Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain
De Castro, Javier (Hospital Universitario La Paz (Madrid))
Insa, Amelia (Hospital Clínic Universitari (València))
Collado-Borrell, Roberto (Hospital General Universitario Gregorio Marañón)
Escudero-Vilaplana, Vicente (Hospital General Universitario Gregorio Marañón)
Martínez, Álex (Hospital Universitari Vall d'Hebron)
Fernández Díaz, Elena (OSI Bilbao-Basurto)
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau)
Arrabal, Natalia (Roche Farma S.A.)
Carcedo, David (Hygeia Consulting)
Manzaneque, Alba (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Universitat Autònoma de Barcelona

Data:	2023
Resum:	There are scarce data of the costs of non-small cell lung cancer (NSCLC) recurrence in Spain. The objective of this study is to assess the economic burden of disease recurrence, for both locoregional and/or metastatic relapses, after appropriate early-stage NSCLC treatment in Spain. A two-round consensus panel of Spanish oncologists and hospital pharmacists was conducted to collect information on patient's flow, treatments, use of healthcare resources and sick leaves in patients with relapsed NSCLC. A decision-tree model was developed to calculate the economic burden of disease recurrence after appropriate early-stage NSCLC. Both direct and indirect costs were considered. Direct costs included drug acquisition and healthcare resources costs. Indirect costs were estimated using the human-capital approach. Unit costs were obtained from national databases (euros of 2022). A multi-way sensitivity analysis was performed to provide a range to the mean values. Among a cohort of 100 patients with relapsed NSCLC, 45 patients would have locoregional relapse (36. 3 would eventually progress to metastasis and 8. 7 would be considered in remission) and 55 patients would have metastatic relapse. Over time, 91. 3 patients would experience a metastatic relapse (55 as first relapse and 36. 6 after previous locoregional relapse). The overall cost incurred by the 100-patients cohort is €10,095,846 (€9,336,782 direct costs, €795,064 indirect costs). The average cost of a locoregional relapse is €25,194 (€19,658 direct costs, €5536 indirect costs), while the average cost a patient with metastasis who receives up to 4 lines of treatment is €127,167 (€117,328 direct, €9839 indirect). To our knowledge, this is the first study that specifically quantifies the cost of relapse in NSCLC in Spain. Our findings shown that the overall cost of a relapse after appropriate treatment of early-stage NSCLC patients is substantial, and it increases considerably in the metastatic relapse setting, mainly due to the high cost and long duration of first-line treatments.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Early-stage NSCLC ; Economic burden ; Locorregional relapse ; Metastatic relapse
Publicat a:	BMC Pulmonary Medicine, Vol. 23 Núm. 1 (december 2023) , p. 69, ISSN 1471-2466

DOI: 10.1186/s12890-023-02356-0
PMID: 36809990

13 p, 2.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats